<DOC>
	<DOC>NCT01478373</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to Imatinib</brief_summary>
	<brief_title>Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically confirmed GIST of any anatomical location, which is 1) unresectable and/ or metastatic with documented disease progression while on therapy with imatinib or 2) surgically removed localized GIST, recurrent on adjuvant imatinib or recurrent within the first 3 months after discontinuation of adjuvant imatinib or 3) patients with unresectable and/or metastatic GIST intolerant to imatinib Positive immunohistochemical staining for cKIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene Documented disease progression according to RECIST (version 1.1) on prior therapy with imatinib at a dose of at least 400mg/day or patients with unresectable and/or metastatic GIST who are intolerant to imatinib At least one measurable GIST lesion according to RECIST (version 1.1). Adequate bone marrow, liver and renal function Patients who have received any other tyrosinekinase inhibitor but imatinib for GIST Patients who received cytotoxic drugs ≤ 4 weeks prior to starting Dovitinib (TKI258) Patients who are treated or planned to be treated concomitantly with other cytotoxic or antineoplastic treatments, such as chemotherapy, immunotherapy, biological response modifiers, or radiotherapy Patients with another primary malignancy within 3 years prior to starting the study drug Patients who have undergone major surgery (e.g. intrathoracic, intraabdominal or intrapelvic) ≤ 4 weeks prior to starting Dovitinib (TKI258) or who have not recovered from the adverse effects of such therapy Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) within the past 6 months Patients with impaired cardiac function or clinically significant cardiac diseases Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dovitinib Patients with prior complete gastrectomy Patients with brain metastasis or history of brain metastasis Patients who are currently receiving anticoagulation treatment with therapeutic doses of warfarin or equivalent anticoagulant Pregnant or breastfeeding women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>GIST</keyword>
	<keyword>Dovitinib</keyword>
</DOC>